AllDocs -> cancers

1 800.955.4572 www.leukemia- lymphoma .org Formerly Leukemia Society of America COMPLEMENTARY & ALTERNATIVE THERAPIES FOR LEUKEMIA, LYMPHOMA , HODGKIN’S DISEASE, & MYELOMA Standard medical treatment for leukemia, lymphoma , Hodgkin’s disease, or myeloma usually involves either chemotherapy, radiation therapy or both. This treatment has been proven through scientific studies to be effective against these cancers and safe for the patient. There is no evidence that anything but current medically approved standard therapy can stem the progression of or cure these cancers. Therefore, standard therapy should not be replaced by any unproven remedy. Although standard treatment has greatly improved survival for individuals with these cancers, the side effects can be difficult. Some persons will wish to seek out other remedies or techniques, sometimes ...

GUIDELINES FOR THE MANAGEMENT OF MALIGNANT LYMPHOMA PUBLIC MEETING Date: MONDAY 15 MARCH 2004 VENUE: STAMFORD AIRPORT HOTEL, SYDNEY AIRPORT TIME: 1000 TO 1600 Kindly supported by INTERNATIONAL GUEST SPEAKERS Dr Michael Pfreundschuh is Professor and Director of the Department of Internal Medicine at the University of Saarland, Homburg, Germany. He is also the lead investigator of the German High Grade non-Hodgkin’s lymphoma study group. Dr Andrew Lister is Professor and Director of the Department of Medical Oncology, St. Bartholomew’s Hospital, London. U.K. His is a major contributor to U.K. Lymphoma and Leukaemia Studies. TOPICS FOR THE DAY WILL INCLUDE Diagnostic Pathology, Hodgkin Lymphoma , Indolent and Aggressive Lymphomas, Extranodal Disease, Complication of Treatment, Consumer Issues REGISTRATION FORM – All attendees must complete ...

Targeted Therapies for Lymphoma For Health Care Professionals and Patients Workbook for the CME Teleconference Wednesday, October 23, 2002 6:00-8:00pm EDT This CE/CME activity is supported by an unrestricted educational grant from IDEC Pharmaceuticals Corporation. Page 2 T a r g e t e d T h e r a p i e s f o r L y m p h o m a An Interactive CME Teleconference – Wednesday, October 23, 2002 Table of Contents Welcome1 Agenda . 2 Participant Instructions . 3 CME Statement 4 Faculty . 5 Faculty Biographies 6 Advances in Immunotherapy for the Treatment of Lymphoma 9 Administration of Radioimmunotherapy and Side Effect Management . 28 CME Post Test Questions . 45 Post Test Answer Sheet & Activity Evaluation 48 This CE/CME activity is supported by an unrestricted ...

ANSWERS ICD-O-3 Coding Exercise Lymphoma and Leukemia Histology Coding Diagnostic Statement Histology/Behavior Grade* 1. ANLL (acute non-lymphocytic leukemia) 9861/3 9 2. B-cell lymphoma 9591/3 6 3. AML t(8;21)(q22;q22) 9896/3 9 4. M2 acute myelocytic leukemia 9874/3 9 5. Mucosal associated lymphoid tissue (MALT) lymphoma 9699/3 9 6. Anaplastic large B-cell lymphoma 9680/3 6 7. Intravascular B-cell lymphoma 9680/3 6 8. Diffuse histiocytic lymphoma 9680/3 9 9. T-cell rich large B-cell lymphoma 9680/3 6 10. Centroblastic lymphoma 9680/3 9 11. Nodular lymphocyte predominant Hodgkin’s disease 9659/3 9 12. Diffuse lymphocyte predominance ...

a report by M V a n G l a b b e k e and I T e o d o r o v i c EORTC Data Center, Brussels I n t r o d u c t i o n For the last 30 years, the European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group has successfully faced the challenge of conducting large international randomised trials in aggressive as well as indolent subtypes of non-Hodgkin’s Lymphoma (NHL). The present paper summarizes the achieved results, and the objectives of on-going projects of the group. I n d o l e n t S u b t y p e s For follicular disease, the group has mainly focussed on the evaluation of new agents. In 1985 a randomised trial was started comparing maintenance treatment with interferon-alpha for one year versus no further treatment in patients with stages III or IV low-grade NHL who had reached a response to cyclophosphamide, ...

Non-Hodgkin lymphoma Cancer survival, incidence and mortality in NSW 1994–2000 58 The Cancer Council NSW Non-Hodgkin lymphoma • The five-year relative survival from non-Hodgkin lymphoma in NSW between 1994 and 2000 was 54.3% • No Area Health Service was different from the State average in the adjusted relative risk of excess death due to non-Hodgkin lymphoma after shrinking • An additional 159 patients would be expected to survive to five years after diagnosis in NSW if the State average risk was shifted to the 20 th centile of the distribution • There were 5,167 new cases of non-Hodgkin lymphoma in NSW in 1994 to 1998 (2,791 males and 2,376 females) and 2,612 deaths (1,361 males and 1,251 females) • There were 49 more new cases of non-Hodgkin lymphoma than expected in males in South Eastern Sydney, and 28 fewer than expected in males in South Western ...

1 MEET THE EXPERT ON NON-HODGKIN LYMPHOMA : N E W I N S I G H T S A N D T R E AT M E N T S MS. BANACKY: My name is Illona Banacky. I was diagnosed with non-Hodgkin lymphoma on November 13, 2003. At the time, my doctor explained that there were a few options available. These included chemotherapy through pills or intravenous therapy, and the most aggressive would be stem cell transplant. When I first diagnosed, I think I went into treatment too quickly. I think before you even opt to go into immediate treatment, do the research first and make sure that you’re comfortable with the doctor and the facility where you are being treated. I think it was important that the doctor and everyone around me — family, friends — understood what I was going through, not just emotionally, but also the treatment options, and helped me decide which road ...

The Thalassemia program at The University Health Network (TGH) Ian Quirt Page 2 The UHN Thalassemia Program – Current Status • We follow 127 (107) adult patients with thalassemia • A large number of patients with sickle cell disease are seen in the same clinic • More than 100 patients are on chronic transfusion programs. • 99 receive parenteral iron chelation Page 3 The UHN Thalassemia Program – Current personnel • One nurse (Bev) acts as the Thalassemia and Sickle Cell Anemia Program Coordinator. She organizes transfusions, supervises and teaches iron chelation therapy and triages telephone calls and drop-in patients (35 hours per week) • One receptionist (Arlene) books all the clinic appointments and consultant visits and arranges for the less common investigations ...

Short Communication Risk of malignant lymphoma associated with human herpesvirus-8: a case–control study in Spain S de Sanjose´* ,1,2 , JJ Goedert 2 , V Marshall 3 , C Bellas 4 , Y Benavente 1 , R Bosch 5 , A Domingo 6 , A Fernandez de Sevilla 7 , O Servitje 8 and D Whitby 3 1 Servei d’Epidemiologia i Registre del Cancer, Institut Catala d’Oncologia, Barcelona, Spain; 2 Viral Epidemiology Branch, National Cancer Institute, Bethesda, MD, USA; 3 Viral Epidemiology Section, AVP, SAIC-Frederick, National Cancer Institute-Frederick, Frederick, MD, USA; 4 Patologia, Ramon y Cajal, Madrid, Spain; 5 Patologia, Hospital Verge de la Cinta, Tortosa, Spain; 6 Hematology, ...

accounting for about 4%-14% of all non-Hodgkin lymphomas in Western countries (2,3). Within the GI tract, the stomach is the most frequent site of involvement constituting up to 10% of all gastric malignancies; its incidence appears to be increasing but this may be due to the recognition of the neo- plastic nature of lesions previously termed "pseudolymphoma" (4). Most cases occur in adults with a median age of 61years and slight preponderance in women (male: female ratio 1:1.2) (5, 6). PRECURSOR LESIONS/CONDITIONS In many cases of MALT lymphoma , there is a history of chronic inflammato- ry, often autoimmune disorders that result in accumulation of extranodal lym- phoid tissue. Examples include Helicobacter pylori associated chronic gastri- tis, Sjögren syndrome of Hashimoto thyroiditis. At an early stage, the tumor is confined to the gastric mucosa and its growth depends critically on H. pylori mediated immunological ...

© 2004, Institute of Oncology Sremska Kamenica,Serbia and Montenegro 67 Case report UDC: 616-006.44:616.383:616-076 INTRODUCTION esenteric lipodystrophy (ML) is a rare condition of unknown etiology that causes nonspecific inflammation and fibrotic process affecting the fatty tissue of the mesentery. Mesenteric lipodystrophy may present as an acute abdomen or with non-specific upper abdominal symptoms. The causative agents are unknown, although an association with lymphoma has been reported. This case report describes the clinic and patholog- ic findings of a large lipoma-like tumor of the mesentery in a 42 years old patient with previous history of lymphoma . CASE REPORT A 42-year-old man presented with weight loss, intermittent con- vulsive abdominal pain, weakness, fatigue, and diarrhea. Patient's history commenced in 1987 with a diagnosis of non-Hodgkin ...